Inhibition of the MEK/ERK pathway reduces microglial activation and interleukin-1-beta expression in spinal cord ischemia/reperfusion injury in rats

Journal of Thoracic and Cardiovascular Surgery

Volumn 133, Issue 4, 2007, Pages 934-941

  Lu, Kang ^a   Cho, Chung Lung ^b   Liang, Cheng Loong ^a   Chen, Shang Der ^c   Liliang, Po Chou ^a   Wang, Shin Yuan ^a   Chen, Han Jung ^a  

^a I SHOU UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; DIMETHYL SULFOXIDE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SURGERY; ARTERY CATHETERIZATION; ARTICLE; BALLOON CATHETER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DESCENDING AORTA; FEMORAL ARTERY; INFLAMMATORY INFILTRATE; MICROGLIA; NERVE CELL; NEUROPATHOLOGY; NOCICEPTIVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SPINAL CORD INJURY; SPINAL CORD ISCHEMIA; THORACIC AORTA;

ANIMALS; BUTADIENES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; INTERLEUKIN-1BETA; MALE; MICROGLIA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRILES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SPINAL CORD ISCHEMIA;

EID: 33947213910     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2006.11.038     Document Type: Article

References (44)

1. Chang L., and Karin M. Mammalian MAP kinase signaling cascades. Nature 410 (2001) 37-40
2. Boulton T.G., Nye S.H., Robbins D.J., Ip N.Y., Radziejewka E., Morgenbesser S.D., et al. ERKs: a family of protein-serine/threonine kinase that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65 (1991) 663-675
3. Nishida E., and Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci 18 (1993) 128-131
4. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greeberg M.E. Opposing effects of ERK and JUNK/p38 MAP kinases on apoptosis. Science 270 (1995) 1326-1331
5. Segal R.A., and Greenberg M.E. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci 19 (1995) 463-489
6. Stanciu M., Wang Y., Kentor R., Burke N., Watkins S., Kress G., et al. Persistent activation of ERK contributes to glutamate induced oxidative toxicity in a neuronal cell line and primary neuron cultures. J Biol Chem 275 (2000) 12200-12206
7. Tang D., Wu D., Hirao A., Lahti J.M., Liu L., Mazza B., et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 277 (2002) 12710-12717
8. Subramaniam S., Zirrgiebel U., von Bohlen Und Halbach O., Strelau J., Laliberte C., Kaplan D.R., et al. ERK activation promotes neuronal degeneration predominantly through plasma membrane damage and independently of caspase-3. J Cell Biol 165 (2004) 357-369
9. Satoh T., Nakatsuka D., Watanabe Y., Nagata I., Kikuchi H., and Namura S. Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons. Neurosci Lett 288 (2000) 163-166
10. Mori T., Wang X., Jung J.C., Sumii T., Singhal A.B., Fini M.E., et al. Mitogen-activated protein kinase inhibition in traumatic brain injury: in vitro and in vivo effects. J Cereb Blood Flow Metab 22 (2002) 444-452
11. Murray B., Alessandrini A., Cole A.J., Yee A.G., and Furshpan E.J. Inhibition of the p44/42 MAP kinase pathway protects hippocampal neurons in a cell-culture model of seizure activity. Proc Natl Acad Sci U S A 95 (1998) 11975-11980
12. Alessandrini A., Namura S., Moskowitz M.A., and Bonventre J.V. MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc Natl Acad Sci U S A 96 (1999) 12866-12869
13. Namura S., Iihara K., Takami S., Nagata I., Kikuchi H., Matsushita K., et al. Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci U S A 98 (2001) 11569-11574
14. Cho D.G., Mullory M.R., Chang P.A., Johnson M.D., Aharon A.S., Robison T.A., et al. Blockade of the extracellular signal-regulated kinase pathway by U0126 attenuates neuronal damage following circulatory arrest. J Thorac Cardiovasc Surg 127 (2004) 1033-1040
15. Pearson V.L., Rothwell N.J., and Toulmond S. Excitotoxic brain damage in the rat induces interleukin-1beta protein in microglia and astrocytes: correlation with the progression of cell death. Glia 25 (1999) 311-323
16. Gibson R.M., Rothwell N.J., and Le Feurvre R.A. CNS injury: the role of the cytokine IL-1. Vet J 168 (2004) 230-237
17. Lucas S.M., Rothwell N.J., and Gibson R.M. The role of inflammation in CNS injury and disease. Br J Pharmacol 147 Suppl 1 (2006) S232-S240
18. Allan S.M., and Rothwell N.J. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2 (2001) 734-744
19. Boutin H., LeFeuvre R.A., Horai R., Asano M., Iwakura Y., and Rothwell N.J. Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 21 (2001) 5528-5534
20. Rothwell N. Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav Immun 17 (2003) 152-157
21. Loddick S.A., Wong M.L., Bongiorno P.B., Gold P.W., Licinio J., and Rothwell N.J. Endogenous interleukin-1 receptor antagonist is neuroprotective. Biochem Biophys Res Commun 234 (1997) 211-215
22. Lazovic J., Gasu A., Lin H.W., Rothstein R.P., Krady J.K., Smith M.B., et al. Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring neuroprotection. Stroke 36 (2005) 2226-2231
23. Wang Z.Q., Wu D.C., Huang F.P., and Yang G.Y. Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia. Brain Res 996 (2004) 55-66
24. Marsala M., and Yaksh T.L. Transient spinal ischemia in the rat: characterization of behavioral and histopathological consequences as a function of the duration of aortic occlusion. J Cereb Blood Flow Metab 14 (1994) 526-535
25. Lu K., Liang C.L., Chen H.J., Chen S.D., Hsu H.C., Liliang P.C., et al. Injury severity and cell death mechanisms: effects of concomitant hypovolemic hypotension on spinal cord ischemia-reperfusion in rats. Exp Neurol 185 (2004) 120-132
26. Duggal N., and Lach B. Selective vulnerability of the lumbosacral spinal cord after cardiac arrest and hypotension. Stroke 33 (2002) 116-121
27. Lau D., Mollnau H., Eiserich J.P., Freeman B.A., Daiber A., Gehling U.M., et al. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci U S A 102 (2005) 431-436
28. Landmann R., Ludwig C., Obrist R., and Obrecht J.P. Effect of cytokines and lipopolysaccharide on CD14 antigen expression in human monocytes and macrophages. J Cell Biochem 47 (1991) 317-329
29. Roy A., Fung Y.K., Liu X., and Pahan K. Up-regulation of microglial CD11b expression by nitric oxide. J Biol Chem 281 (2006) 14971-14980
30. Gonzalez-Scarano F., and Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 22 (1999) 219-240
31. Ling E.A., and Wong W.C. The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia 7 (1993) 9-18
32. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22 (2002) 1763-1771
33. Barcia C., Sanchez Bahillo A., Fernandez-Villalba E., Bautista V., Poza Y., Poza M., Fernandez-Barreiro A., et al. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 46 (2004) 402-409
34. Rock R.B., Gekker G., Hu S., Sheng W.S., Cheeran M., Lokensgard J.R., et al. Role of microglia in central nervous system infections. Clin Microbiol Rev 17 (2004) 942-964
35. Mabuchi T., Kitagawa K., Ohtsuki T., Kuwabara K., Yagita Y., Yanagihara T., et al. Contribution of microglia/macrophages to expansion of infarction and response of oligodendrocytes after focal cerebral ischemia in rats. Stroke 31 (2000) 1735-1743
36. Hazan I., Dana R., Granot Y., and Levy R. Cytosolic phospholipase A2 and its mode of activation in human neutrophils by opsonized zymosan. Correlation between 42/44 kDa mitogen-activated protein kinase, cytosolic phospholipase A2 and NADPH oxidase. Biochem J 326 (1997) 867-876
37. Wheeler-Jones C., Abu-Ghazaleh R., Cospedal R., Houliston R.A., Martin J., and Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 420 (1997) 28-32
38. Zhang C., Baumgartner R.A., Yamada K., and Beaven M.A. Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-alpha and release of arachidonic acid in mast cells. Indications of communication between p38 and p42 MAP kinases. J Biol Chem 272 (1997) 13397-13402
39. Newton R., Cambridge I., Hart L.A., Stevens D.A., Lindsay M.A., and Barnes P.J. The MAP kinase inhibitors, PD098059, U0126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes. Br J Pharmacol 130 (2000) 1353-1361
40. Eng L.F., and Ghirnikar R.S. GFAP and astrogliosis. Brain Pathol 4 (1994) 229-237
41. Faulkner J.R., Herrmann J.E., Woo M.J., Tansey K.E., Doan N.B., and Sofroniew M.V. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 24 (2004) 2143-2155
42. Rudge J.S., and Silver J. Inhibition of neuritic growth on astroglial scars in vitro. J Neurosci 10 (1990) 3594-3603
43. McKeon R.J., Schreiber R.C., Rudge J.S., and Silver J. Reduction of neuritic outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. J Neurosci 11 (1991) 3398-3411
44. Menet V., Gimenez y Ribotta M., Chauvet N., Drian M.J., Lannoy J., Collucci-Guyon E., et al. Inactivation of the glial fibrillary acidic protein gene, but not that of vimentin, improves neuronal survival and neuritic growth by modifying adhesion molecule expression. J Neurosci 21 (2001) 6147-6158